Established in Sweden as a small spinout of AstraZeneca in 2008, Albireo always had big ambitions. After all, it was named after the striking “double …
If there is one strong message Camille Hertzka, AstraZeneca vice president and head of oncology, U.S. medical, wants people to take away from lung cancer …
People in the U.S. with conditions that prevent them from building immunity with COVID-19 vaccines will soon have a way to get adequate protection from …
Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting …
AstraZeneca’s chief executive Pascal Soriot is challenging the notion that his company’s vaccine is inferior to the mRNA vaccines from Moderna and Pfizer. In fact, …
Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson’s Invokana is vying for a piece of the lucrative heart failure market. J&J’s Type …
Over the years, AstraZeneca has consistently adjusted its portfolio, targeting aging products. The company has now found a new home for two respiratory meds with an …
At times during the pandemic, there’s been no love lost between AstraZeneca and the EU. After the U.K. pharma giant fell behind on its planned …
AstraZeneca and Daiichi Sankyo’s Enhertu is shouldering big expectations. With a new head-to-head trial win against Roche’s Kadcyla, the companies are showing their antibody-drug conjugate …
The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
